HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

C Langenaken Selected Research

Therapeutics

1/2015Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


C Langenaken Research Topics

Disease

2Rheumatoid Arthritis
11/2022 - 01/2015
1Rheumatic Diseases (Rheumatism)
01/2015
1Joint Diseases (Joint Disease)
01/2015

Drug/Important Bio-Agent (IBA)

1Etanercept (Enbrel)FDA Link
11/2022
1Antirheumatic Agents (DMARD)IBA
11/2022
1C-Reactive ProteinIBA
01/2015
1GlucocorticoidsIBA
01/2015
1W 7 (W7)IBA
01/2015
1Methotrexate (Mexate)FDA LinkGeneric
01/2015
1Prednisone (Sone)FDA LinkGeneric
01/2015
1ametantrone (HAQ)IBA
01/2015
1Leflunomide (Arava)FDA LinkGeneric
01/2015

Therapy/Procedure

1Remission Induction
01/2015
1Therapeutics
01/2015